Monday, 24 Feb 2020

You are here

Ustekinumab Efficacy in Ulcerative Colitis

The NEJM reports the results of a one year trial wherein ustekinumab (UST) was shown to be effective at inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. Ustekinumab, currently approved for use in psoriasis, psoriatic arthritis and Crohn's disease, is a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23.

The study included 961 patients with moderate-to-severe ulcerative colitis who received intravenous placebo (PBO) or UST as 8-week induction therapy and 44-week maintenance therapy in patients. The primary end point was clinical remission (defined as a total score of ≤2 on the Mayo scale).

At the end of 8 weeks, clinical remission was significantly higher with ustekinumab 130 mg (15.6%) or 6 mg/kg (15.5%) than that placebo (5.3%) (P<0.001). 

Responders to induction therapy also had higher clinical remission rates at week 44 with 90 mg subcutaneous UST (q 12 wks) (38.4%) or every 8 weeks (43.8%) than among those assigned to placebo (24.0%) (P=0.002 and P<0.001, respectively).

Serious adverse events were similar between UST and PBO. At one year there were two deaths and cancers in the 825 UST treated patients compared to no deaths and one cancer for the 319 patients on PBO.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Tofacitinib Effective in Refractory Still's Disease

Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in patients with refractory adult-onset Still’s disease (AOSD), further adding to a growing list of potential use of JAK inhibition in managing inflammatory, and now autoinflammatory, disease.

QD Clinic - Hepatitis B and Biologics

QD Clinic - Lessons from the clinic Active HBV infection (HGsAg+) on anti-viral therapy but needs a biologic - what should you use?

Biosimilars for Rheum Disease: Failure to Launch

The availability of biologic biosimilars has thus far had negligible impact on prescribing practices in the United States, in stark contrast to what has been observed in some European countries, researchers reported.

Best of 2019 - Is Methotrexate Necessary with Tofacitinib?

Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid.

Best of 2019 - Ups and Downs with Abatacept

Two recent studies have examined the effect of starting abatacept upon the risk of serious hospitalized infections or cancer, showing divergent results from claims data analyses.